Biocre Tech, a Chinese synthetic biology startup, announced that it had completed a pre-A round of financing of nearly 50 million yuan. This round of financing will be mainly used for biosynthesis of targeted bactericidal protein and functional peptides, so as to accelerate the product layout in the fields of efficacy skin health, pet intestinal health, and rare metabolic diseases, and plan to establish the first phase of industrialized production base, team talent introduction, and business development team construction.

Since the establishment, Biocre Tech has insisted on building a protein precise design & protein molecular machine technology platform and developed powerful protein components in combination with biological big data machine learning and rational design. On this basis, the directed evolution of protein molecules is carried out to further improve the performance of protein. Biocre Tech uses an intelligent automatic high-throughput screening system and efficient gene-editing technology to build a protein machine with high synergistic effect, so as to quickly construct the metabolic synthesis pathway of products in cells, design and develop efficient cell factories, and greatly improve the synthesis efficiency.

Based on this synthetic biology development logic, Biocre Tech modularizes the production process of biosynthesis, constructs "plug and play" biological components, and efficiently creates the metabolic pathways of target products in the chassis cell factory, paving the way for the rapid design of drug synthesis route and the synthesis of super biocatalytic enzymes. Biocre Tech team can quickly produce high value-added products for different application scenarios, such as targeted bactericidal proteins, functional peptides, artificial functional proteins, and intestinal administration medical enzymes.